Processing

Please wait...

Settings

Settings

Goto Application

1. WO2017017469 - CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS

Publication Number WO/2017/017469
Publication Date 02.02.2017
International Application No. PCT/GB2016/052332
International Filing Date 28.07.2016
IPC
C07F 5/02 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
FACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
5Compounds containing elements of Groups 3 or 13 of the Periodic System
02Boron compounds
CPC
C07F 5/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
5Compounds containing elements of Groups 3 or 13 of the Periodic System
02Boron compounds
Applicants
  • THE UNIVERSITY OF MANCHESTER [GB]/[GB]
Inventors
  • BROUGH, David
  • ALLAN, Stuart McRae
  • FREEMAN, Sally
  • BALDWIN, Alex George
Agents
  • WELLS, Andrew
  • HGF LIMITED
Priority Data
1513481.030.07.2015GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS
(FR) DÉRIVÉS DE DIARYLBORON CYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS D'INFLAMMASOME NLRP3
Abstract
(EN)
Inhibitor compounds are disclosed. The compounds are effective in the treatment of diseases or conditions in which interleukin 1 β activity is implicated. Methods of synthesis of the compounds, as well as pharmaceutical compositions comprising the compounds are also disclosed.
(FR)
L'invention concerne des composés inhibiteurs. Les composés sont efficaces dans le traitement de maladies ou d'états dans lesquels l'activité de l'interleukine 1β est impliquée. L'invention concerne également des méthodes de synthèse des composés, ainsi que des compositions pharmaceutiques comprenant les composés.
Also published as
Latest bibliographic data on file with the International Bureau